The Medical Letter on Drugs and Therapeutics
ONLINE
ONLY
ARTICLE
ONLY
ARTICLE
February 19, 2024
Repotrectinib (Augtyro) for Non-Small Cell Lung Cancer (online only)
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Repotrectinib (Augtyro) for Non-Small Cell Lung Cancer (online only)
February 19, 2024 (Issue: 1696)
The FDA has approved the oral tyrosine kinase
inhibitor repotrectinib (Augtyro – BMS) for treatment
of locally advanced or metastatic ROS1-positive
non-small cell lung cancer (NSCLC) in adults.
Repotrectinib is the third oral tyrosine kinase...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.